Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in thymic carcinoma
CTR20201006Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Jun 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in thymic carcinoma (TC), sponsored by Alphamab Oncology. Started Jun 2020; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20201006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201006.